Overview

Neuroinflammation in Hypertension Study

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

Phase:

Phase 3

Details

Lead Sponsor:

Royal Perth Hospital

Treatments:

Minocycline